Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

26
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
26
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

29
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
29
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

27
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
27
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

46
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
46
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

31
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
31
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

45
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
45

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibronectin-induced overactivation of α<sub>V</sub>β<sub>3</sub>-PI3K-PIP3-PDK1-ILK signaling drives aortic disease in Marfan syndrome.

Nature communications·2026
Same author

De-extinction of the Northern white rhinoceros (Ceratotherium simum cottoni).

The Journal of reproduction and development·2026
Same author

Nonsyndromic familial type B aortic dissection exhibits distinct clinical profiles and operative outcomes.

Journal of vascular surgery·2026
Same author

Vatican Revisits Ethics and Science of Xenotransplantation as Clinical Trials Advance.

The Linacre quarterly·2026
Same author

Vatican Reaffirms Moral Permissibility of Xenotransplantation.

Xenotransplantation·2026
Same author

Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy.

Cell·2026

Related Experiment Video

Updated: Aug 22, 2025

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.1K

Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study.

Manuel Galiñanes1,2, Kelly Casós1,3, Arnau Blasco-Lucas1,2,4

  • 1Reparative Therapy of the Heart, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron, 119; Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain.

Biomolecules
|November 11, 2022
PubMed
Summary

Oxidative stress markers like malondialdehyde and nitrotyrosine increase after bioprosthetic heart valve implantation. These markers decrease as structural valve deterioration develops, suggesting a role for oxidative stress in bioprosthetic heart valve dysfunction.

Keywords:
aortic valvebiological heart valveslipid peroxidationoxidative stressprotein nitrationstructural valve deteriorationtranscatheter aortic valve implantation

More Related Videos

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.4K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

2.8K

Related Experiment Videos

Last Updated: Aug 22, 2025

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.1K
Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.4K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

2.8K

Area of Science:

  • Biomaterials Science
  • Cardiovascular Research
  • Oxidative Stress Studies

Background:

  • Structural valve deterioration (SVD) is a primary limitation of bioprosthetic heart valves (BHVs).
  • The precise mechanisms driving SVD remain incompletely understood.
  • Oxidative stress is implicated in various biological processes and tissue damage.

Purpose of the Study:

  • To investigate the association between specific oxidative stress markers and SVD in patients with BHVs.
  • To evaluate the temporal changes in oxidative stress markers following BHV implantation.
  • To determine if oxidative stress levels differ between patients with and without SVD.

Main Methods:

  • Serum samples were collected from patients with SVD and BHV patients at various time points post-implantation (0-24 months and >48 months).
  • Assays were performed to measure total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT) levels.
  • Statistical analysis was used to compare marker levels between groups and over time.

Main Results:

  • Malondialdehyde (MDA) levels increased early post-surgery, with higher levels at 6 months in incipient SVD patients.
  • Nitrotyrosine (NT) levels showed a gradual increase within the first 24 months post-implantation.
  • Transcatheter aortic valve implantation (TAVI) patients exhibited elevated stress markers; MDA and NT levels decreased in established SVD groups after 48 months.

Conclusions:

  • Oxidative stress plays a significant role in BHV dysfunction, particularly early after implantation and in TAVI cases.
  • While oxidative stress markers increase post-implantation, their levels decrease as SVD progresses.
  • Oxidative stress markers may serve as potential therapeutic targets and biomarkers for BHV dysfunction.